WO2002010163A1 - Process for preparing azacycloalkanoylaminothiazoles - Google Patents
Process for preparing azacycloalkanoylaminothiazoles Download PDFInfo
- Publication number
- WO2002010163A1 WO2002010163A1 PCT/US2001/014155 US0114155W WO0210163A1 WO 2002010163 A1 WO2002010163 A1 WO 2002010163A1 US 0114155 W US0114155 W US 0114155W WO 0210163 A1 WO0210163 A1 WO 0210163A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- recited
- alkyl
- aryl
- acid
- solvent
- Prior art date
Links
- 0 CC*C(C(*)=O)[N+]1(C[N-]C2)CN2CN(C)C1 Chemical compound CC*C(C(*)=O)[N+]1(C[N-]C2)CN2CN(C)C1 0.000 description 2
- RSRXCHPAHIURPZ-UHFFFAOYSA-N CCN1CN(CNC2)CN2C1 Chemical compound CCN1CN(CNC2)CN2C1 RSRXCHPAHIURPZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention concerns new processes for the preparation of 5-(2- oxazolylalkylthio)-2-azacycloalkanoylaminothiazoles and analogs, inhibitors of cyclin dependent kinases.
- R is alkyl, aryl or heteroaryl
- R 1 , R 2 , R 3 , R 4 and R 5 are each independently hydrogen, alkyl, aryl or heteroaryl;
- R 6 and R 7 are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy;
- R 8 is hydrogen, alkyl, aryl, heteroaryl, CONR 9 R 10 , COR 1 ' or COOR 12 ;
- R 9 , R 10 , R 11 and R 12 are each independently hydrogen, alkyl or aryl; m equals 0 to 5; and n equals 0 to 5, are novel, potent inhibitors of cyclin dependent kinases (cdks). They are useful in the therapy of proliferative diseases, for example, cancer, inflammation, autoimmune diseases such as arthritis, viral diseases, fungal diseases, chemotherapy-induced alopecia, neurodegenerative disorders such as Alzheimer's disease and cardiovascular disease. More specifically, the compounds of formula I are useful in the treatment of a variety of cancers such as bladder, breast, colon, kidney, liver and lung cancers. WO 9924416 and corresponding U.S. Patent No.
- This invention concerns new efficient processes for the preparation of 5-(2- oxazolylalkylthio)-2-aminothiazoles.
- the processes involve new strategies for the preparation of 2-oxazolylalkyl halides and 5-(2-oxazolylalkylthio)-2-aminothiazoles which include the method of making new key intermediate quaternary ammonium salts and 2-oxazolylalkyl sulfide derivatives.
- This invention further relates to processes for the preparation of 5-(2-oxazolylalkylthio)-2-azacycloalkanoylaminothiazoles and analogs, inhibitors of cyclin dependent kinases.
- the present invention relates to new, more efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-aminothiazoles with application to the synthesis of 5-(2- oxazolylalkylthio)-2-azacycloalkanoylaminothiazoles and analogs, inhibitors of cyclin
- the process generally involves reaction of ⁇ -halo ketones II with an
- the process of the present invention preferably utilizes the Burgess' reagent which produces excellent yields and permits easy, safe product isolation from water.
- 2-oxazolylalkyl halides VII with sulfur-containing reagent VIII or VIII' affords new key intermediate compounds, 2-oxazolylalkyl sulfides IX.
- Coupling of IX with 5-halo-2-aminothiazole X gives 5-(2-oxazolylalkylthio)-2- aminothiazoles XL
- Coupling of XI with an azacycloalkanoic acid derivative XII affords thiazolyl amides XIII, which may be deprotected (in the case where P is a protecting group, e.g., Boc) to give 5-(2-oxazolylalkylthio)-2-azacycloalkanoylaminothiazoles I, where R is hydrogen, inhibitors of cyclin dependent kinases.
- R is alkyl, aryl or heteroaryl
- R 1 , R 2 , R 3 , R 4 and R 5 are each independently hydrogen, alkyl, aryl or heteroaryl; R and R are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy;
- R 8 is hydrogen, alkyl, aryl, heteroaryl, CONR 9 R 10 , COR 11 or COOR 12 ;
- R 9 , R 10 , R 11 and R 12 are each independently hydrogen, alkyl or aryl;
- L is halogen or sulfonate (RSO 2 O-, CF 3 SO 2 O-, etc.);
- M is hydrogen, Li, Na, K, Cs or quaternary ammonium (R N);
- X is hydroxy, halogen or acyloxy (RCOO-, ROCOO-, etc.);
- Y is O, S, NH, N-alkyl, N-aryl or N-acyl;
- Z is hydrogen, alkyl, aryl, O-alkyl, O-aryl, S-alkyl, S-aryl, NH 2 , N-alkyl, N-aryl or N- acyl;
- P is a nitrogen-protecting group (Boc, Cbz, R 3 Si, etc.); m equals 0 to 5; and n equals 0 to 5.
- alkyl or “alk” (i.e., derivative forms of alkyl) refers to optionally substituted straight chain, branched or cyclic monovalent alkane (saturated hydrocarbon) derived radicals containing from 1 to 12 carbon atoms. When substituted, alkyl groups may be substituted with up to four substituent groups at any available point of attachment.
- alkyl groups include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, isobutyl, pentyl, hexyl, isohexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and the like.
- the alkyl can be optionally substituted with one or more halogens or alkyl groups such as, for example, trifluoromethyl, 4,4-dimethylpentyl, 2,2,4-trimethylpentyl, etc.
- aryl refers to monocyclic or bicyclic aromatic rings, e.g., phenyl, substituted phenyl and the like, as well as groups which are fused, e.g., napthyl, phenanthrenyl and the like, containing from 6 to 30 carbon atoms.
- An aryl group can thus contain at least one ring having 6 atoms, with up to five such rings being present, containing up to 22 or 30 atoms therein, depending upon optionally alternating (resonating) double bonds between carbon atoms or suitable heteroatoms.
- aryl groups include, but are not limited to, phenyl, naphthyl, anthryl, biphenyl and the like.
- acyl refers to the radical RCO-, taken alone or in combination, for example, with oxygen, nitrogen, sulfur, etc.
- halogen or halo refers to chlorine, bromine, fluorine or iodine, with bromine being the preferred halogen.
- heteroaryl refers to a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing at least one heteroatom, O, S or N, in which a carbon or nitrogen atom is the point of attachment, and in which one or two additional carbon atoms is optionally replaced by a heteroatom selected from O or S, and in which from 1 to 3 additional carbon atoms are optionally replaced by nitrogen heteroatoms, said heteroaryl group being optionally substituted as described herein.
- heteroaryl groups include, but are not limited to, thienyl, furyl, pyrrolyl, pyridinyl, imidazolyl, pyrrolidinyl, piperidinyl, thiazolyl, oxazolyl, triazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyrazinyl, pyridazinyl, pyrimidinal, triazinylazepinyl, indolyl, isoindolyl, quinolinyl, isoquinolinyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, benzoxadiazolyl, benzofurazanyl, etc.
- protecting groups for the compounds involved in the present processes will be recognized from the specification taking into account the level of skill in the art, and with reference to standard textbooks such as T. W. Greene et al, Protective Groups in Organic Synthesis, Wiley, N.Y. (1991).
- salts of the biologically active compounds which do not significantly or adversely affect the pharmaceutical properties of the compounds such as, for example, toxicity, efficacy, etc. and include those salts which are conventionally employed in the pharmaceutical industry. Suitable examples of salts include, but are not limited to, those formed with inorganic or organic acids such as hydrochloride, hydrobromide, sulfate, phosphate, etc. Also included, particularly for the intermediate compounds of the invention, are salts which are unsuitable for pharmaceutical utility but which can be employed otherwise, for example, for isolation or purification of free active compounds or their pharmaceutically acceptable salts.
- All stereoisomers of the compounds of the instant invention are contemplated, either in admixture or in pure or substantially pure form.
- the definition of the compounds employed in the processes of the invention embraces all possible stereoisomers and their mixtures.
- the definition further embraces the racemic forms and the isolated optical isomers having the specified activity.
- the racemic forms can be resolved by physical methods such as, for example, fractional crystallization, separation or crystallization of diastereomeric derivatives or separation by chiral column chromatography.
- the individual optical isomers can be obtained from the racemates by conventional methods such as, for example, salt formation with an optically active acid followed by crystallization.
- solvates e.g., hydrates
- Methods of solvation are generally known in the art. Therefore, the compounds useful in the processes of this invention may be in the free or hydrate form.
- the ⁇ -halo ketone includes ⁇ -halo aliphatic and ⁇ -halo aromatic ketones.
- ⁇ -halo ketones are ⁇ -halo pinacolones with ⁇ -bromo pinacolone most
- a sulfonate for example, RSO 2 O- (where R is alkyl, aryl or heteroaryl),
- the metal azides include both metal azides and quaternary ammonium azides.
- the metal azides are
- Suitable solvent(s) include solvents such as
- hydrocarbons for example, dimethylformamide, ketones, etc., or mixtures thereof, with ketones such as acetone preferred for both reactions (a) and (a 1 ).
- step (b) reacting the ⁇ -azido ketone III obtained in step (a) with a reducing reagent in
- step (b') reacting the quaternary ammonium salt III' obtained in step (a') with an acid in a
- the reducing reagent in reaction (b) includes hydrogen in the presence of a transition metal catalyst such as palladium, trialkyl or triarylphosphines like triphenylphosphine. Hydrogen in the presence of a transition metal catalyst is preferred with hydrogen and palladium over activated carbon most preferred.
- Suitable solvent(s) in reaction (b) include solvents such as hydrocarbons, ethers, alcohols and the like, or mixtures thereof, with alcohol such as methanol preferred.
- the reduction reaction can be carried out in the presence of an acidic medium such as, for example,
- the acid in reaction (b') includes, but is not limited to, protic acids such as HC1,
- Suitable solvent(s) in reaction (b') include solvents such as hydrocarbons, ethers, alcohols and the like, or mixtures thereof,
- the ⁇ -amino ketone product may be isolated as
- step (c) reacting (acylating) the ⁇ -amino ketone IV or its acid salt obtained in step (b)
- acyl derivative V such as, for example, an ⁇ -halo acyl
- the ⁇ -halo acyl halide V includes ⁇ -alkyl or aryl substituted or unsubstituted ⁇ -
- halo acyl halide with the latter preferred.
- the most preferred ⁇ -halo acyl halide is ⁇ -
- the base used in the reaction includes, but is not limited to, aromatic and aliphatic organic amines with the latter preferred. The most preferred base is triethylamine.
- Suitable solvent(s) include aprotic solvents such as hydrocarbons, halogenated hydrocarbons, ethers, esters and the like, or mixtures thereof, with halogenated hydrocarbons such as dichloromethane preferred.
- a coupling reagent such as a water-soluble diimide like carbodiimide, haloformate, thionyl halide, etc.
- a coupling reagent such as a water-soluble diimide like carbodiimide, haloformate, thionyl halide, etc.
- a sulfonate for example, RSO 2 O- (where R is an alkyl, aryl or heteroaryl), CF 3 SO 2 O- and the like, may
- step (d) reacting the amide VI obtained in step (c) with a dehydrating reagent in a suitable solvent or solvent mixtures to give the cyclized 2-oxazolylalkyl derivative VII such as, for example, the 2-oxazolylalkyl halide.
- the reaction is carried out using (methoxycarbonylsulfamoyl)- triethylammonium hydroxide (Burgess' reagent) as the dehydrating reagent.
- Suitable solvent(s) include hydrocarbons, halogenated hydrocarbons, ethers and the like, or mixtures thereof. Most preferred is the use of the Burgess' reagent in tetrahydrofuran.
- Suitable dehydrating reagents also include, but are not limited to, other bases, acids, acid anhydrides and the like, such as, e.g., concentrated sulfuric acid, polyphosphoric acid, etc.
- the dehydrating reagent for instance, can be trihalophosphorus oxide such as tribromophosphorus oxide or trichlorophosphorus oxide, alone or with a solvent like toluene.
- step (e) reacting the 2-oxazolylalkyl derivative VII obtained in step (d) with a sulfur- containing reagent VIII or NIII' in a suitable solvent or solvent mixtures to give 2- oxazolylalkyl sulfide IX, a new key intermediate compound.
- the sulfur-containing reagent includes ⁇ -substituted or unsubstituted thioureas, thio acids or salts such as thioacetic acid or its salt, xanthic acids or salts such as ethylxanthic acid potassium salt. Unsubstituted thiourea is preferred.
- Suitable solvent(s) include hydrocarbons, halogenated hydrocarbons, ethers, esters, amides, alcohols and the like, or mixtures thereof, with alcohol such as methanol or ethanol preferred.
- step (f) reacting the 2-oxazolylalkyl sulfide IX obtained in step (e) with a 5-halo-2- aminothiazole X in the presence of a base and in a suitable solvent or solvent mixtures to give 5-(2-oxazolylalkylthio)-2-aminothiazole XL
- the 5-halo-2-aminothiazole includes 4,N-substituted or unsubstituted 5-halo-2- aminothiazoles with 5-bromo-2-aminothiazole preferred.
- a suitable base includes, but is not limited to, metal hydroxide, metal alkoxides, metal carbonates and aqueous amines such as ammonium hydroxide. Sodium hydroxide is preferred.
- Suitable solvent(s) include solvents such as hydrocarbons, halogenated hydrocarbons, ethers, esters, amides, alcohols and the like, or mixtures thereof, with halogenated hydrocarbons such as dichlorome
- step (g) reacting the 5-(2-oxazolylalkylthio)-2-aminothiazole XI obtained in step (f) with an azacycloalkanoic acid derivative XII in the presence of a coupling reagent in a suitable solvent or solvent mixtures to give thiazolyl amide XIII.
- the azacycloalkanoic acid derivative includes N-protected derivatives, for example, N-protected isonipecotic acid or N-protected nipecotic acid.
- the preferred nitrogen-protecting groups are Boc, Cbz, silicon derivatives and the like with Boc being the most preferred.
- the coupling reagent includes, but is not limited to, water-soluble carbodiimides, haloformates and the like, with carbodiimides such as alkylcarbodiimides being preferred.
- Suitable solvent(s) include solvents such as hydrocarbons, halogenated hydrocarbons, ethers, esters, amides, etc., or mixtures thereof, with halogenated hydrocarbons such as dichloromethane preferred.
- step (h) reacting the thiazolyl amide XIII obtained in step (g) with a deprotecting reagent in a suitable solvent or solvent mixtures to give a desired 5-(2-oxazolylalkylthio)- 2-azacycloalkanoylaminothiazole I (where R 7 is hydrogen).
- the choice of the deprotecting reagent is based on the nature of the protecting group (P).
- the preferred deprotecting reagent is an acid such as hydrochloric acid or trifluoroacetic acid and suitable solvent(s) for such deprotecting reaction include solvents such as hydrocarbons, halogenated hydrocarbons, ethers, esters, amides and the like, or mixtures thereof, with halogenated hydrocarbons such as dichloromethane preferred.
- suitable solvent(s) for such deprotecting reaction include solvents such as hydrocarbons, halogenated hydrocarbons, ethers, esters, amides and the like, or mixtures thereof, with halogenated hydrocarbons such as dichloromethane preferred.
- the starting compounds of Scheme 1 are commercially available or may be prepared by methods known to one of ordinary skill in the art.
- ⁇ -Bromo-pinacolone (179 g, 1 mol, 1 eq) was combined in 2 L of acetone with hexamethylenetetramine (154.21 g, 1.1 mol, 1.1 eq) and the reaction stirred under N 2 at room temperature for 26 hours. The resulting slurry was filtered, the filter cake was washed with ether (3 x 50 mL) and dried in vacuo at 50°C overnight to provide 330 g (100%) of the title compound containing 7% hexamethylenetetramine.
- HPLC R.T. 0.17 min (Phenomenex Inc., 5 ⁇ m C18 column 4.6 x 50 mm, 10-90% aqueous methanol over 4 minutes containing 0.2% phosphoric acid, 4 mL/min, monitoring at 220 nm).
- ⁇ -Azido-pinacolone (128.5 g, 0.911 mol) was combined in 4.2 L of methanol with 77.1 mL of concentrated HC1 and 15.42 g of 10% Pd/C. The reaction mixture was stirred under hydrogen for 1.5 hours. The catalyst was removed by filtration. The solvent was distilled to give a wet solid. The residual water was azeotropically removed with isopropanol (2 x 500 mL). Tert-butyl methyl ether (300 mL) was added and the resulting slurry was stirred, filtered, washed with t-butyl methyl ether (3 x 100 mL) and dried to give 131.0 g (95.5%) of the title compound.
- Example 4 The title compound of Example 4 (130.96 g, 0.8637 mol, 1 eq) was dissolved in 3.025 L of CH 2 C1 2 under N 2 at -5°C. Triethylamine (301 mL, 2.16 mol, 2.5 eq) was added, followed by chloroacetyl chloride (75.7 mL, 0.450 mol, 1.1 eq) in 175 mL of
- Example 5 The title compound of Example 5 (180.13 g, 0.9398 mol, 1 eq) was combined with phosphorus oxychloride (262 mL, 2.8109 mol, 3 eq) under N 2 . The reaction was heated at 105°C for 1 hour, the mixture was cooled to room temperature, and quenched with 1.3 kg of ice. The aqueous phase was extracted with ethyl acetate (1 L, then 2 x 500 mL). The organic extracts were washed with saturated aqueous NaHCO 3 (4 x 1 L) which was back-extracted several times with ethyl acetate.
- Example 5 the title compound of Example 5 (10.0 g, 52.17 mmol, 1 eq.) in 50 mL of tetrahydrofuran (THF) was combined with (methoxycarbonylsulfamyl)- triethylammonium hydroxide (Burgess' reagent, 105.70 mmol, 2.03 eq., generated in situ from 9.2 mL of chlorosulfonyl isocyanate, 4.4 mL of methanol and 14.8 mL of triethylamine in 100 mL THF). The reaction was heated to 45°C for 1.5 hours. After cooling to room temperature, the reaction was quenched with water (50 mL).
- THF tetrahydrofuran
- Example 6 The title compound of Example 6 (1.77 g, 10.2 mmol, 1.02 eq) was combined with thiourea (0.76 g, 9.98 mmol, 1 eq) under N 2 in 10 mL of absolute ethanol. The reaction was heated at reflux for 1.5 hours. The mixture was cooled to room temperature and concentrated in vacuo. Trituration of the resulting crude material with t-butyl methyl ether provided 2.32 g (93%) of the title compound.
- Example 7 The title compound of Example 7 (1.25 g, 5 mmol, 1 eq) was added to a mixture of NaOH (3.0 g, 75 mmol, 15 eq), water (10 mL), toluene (10 mL) and tetrabutylammonium sulfate (50 mg, 0.086 mmol, 0.017 eq).
- 5-Bromo-2-aminothiazole hydrobromide (1.70 g, 5 mmol, 1 eq) was added and the reaction was stirred at room temperature for 14.5 hours.
- Example 8 The title compound of Example 8 (9.6 g, 35.6 mmol) was dissolved in N,N- dimethylformamide (36 mL) and CH2CI2 (100 mL), to which was added l-(3- dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (13.8 g, 72 mmol, 2 eq), N-t- butoxycarbonyl-azacycloalkanoic acid (12.6 g, 55 mmol, 1.5 eq), and A- - (dimethylamino)pyridine (2 g, 16 mmol, 0.45 eq). The clear reaction mixture became cloudy as it was stirred at room temperature for 3.5 hours.
- Example 9 The title compound of Example 9 (16.6 g) was dissolved in 150 mL of CH2CI2, trifluoroacetic acid (30 mL) was added dropwise, and the mixture was stirred at room temperature for 2 hours. The reaction was concentrated in vacuo, diluted with water (300 mL), cooled in ice, made basic with sodium hydroxide, and the resulting solid filtered and recrystallized from ethanol, water and methanol to provide 11.2 g (83%) of the title compound as a yellow solid.
- the white solid hydrochloride could be obtained by addition of 18 mL of IN aqueous HCI to 7 g of this material in methanol.
Abstract
Description
Claims
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU0301649A HUP0301649A3 (en) | 2000-07-26 | 2001-05-02 | Process for preparing azacycloalkanoylaminothiazoles |
AT01932879T ATE299878T1 (en) | 2000-07-26 | 2001-05-02 | METHOD FOR PRODUCING AZACYCLOALKANOYLAMINOTHIAZOLES |
CA002417260A CA2417260A1 (en) | 2000-07-26 | 2001-05-02 | Process for preparing azacycloalkanoylaminothiazoles |
KR1020037001143A KR100764949B1 (en) | 2000-07-26 | 2001-05-02 | Process for Preparing Azacycloalkanoylaminothiazoles |
AU5936901A AU5936901A (en) | 2000-07-26 | 2001-05-02 | Process for preparing azacycloalkanoylaminothiazoles |
JP2002515892A JP2004505080A (en) | 2000-07-26 | 2001-05-02 | Method for producing azacycloalkanoylaminothiazole |
BR0112748-9A BR0112748A (en) | 2000-07-26 | 2001-05-02 | Process for the preparation of azacycloalkanoyl aminothiazoles |
IL15374801A IL153748A0 (en) | 2000-07-26 | 2001-05-02 | Processes for preparing azacycloalkanoylaminothiazole derivatives |
DE60112091T DE60112091T2 (en) | 2000-07-26 | 2001-05-02 | PROCESS FOR THE PREPARATION OF AZACYCLOALKANOYLAMINOTHIAZOLENE |
MXPA03000685A MXPA03000685A (en) | 2000-07-26 | 2001-05-02 | Process for preparing azacycloalkanoylaminothiazoles. |
DK01932879T DK1303514T3 (en) | 2000-07-26 | 2001-05-02 | Process for the preparation of azacycloalkanoylaminothiazoles |
AU2001259369A AU2001259369B2 (en) | 1999-12-15 | 2001-05-02 | Process for preparing azacycloalkanoylaminothiazoles |
EP01932879A EP1303514B9 (en) | 2000-07-26 | 2001-05-02 | Process for preparing azacycloalkanoylaminothiazoles |
IL153748A IL153748A (en) | 2000-07-26 | 2002-12-30 | Processes for preparing azacycloalkanoylaminothiazole derivatives |
HK03103394A HK1052928A1 (en) | 2000-07-26 | 2003-05-13 | Process for preparing azacycloalkanoylaminothiazoles |
CY20051101065T CY1105666T1 (en) | 2000-07-26 | 2005-09-02 | PROCESS FOR THE PREPARATION OF AZACYCLOALKANOYLAMINOTHIAZOLES |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61662700A | 2000-07-26 | 2000-07-26 | |
US09/616,627 | 2000-07-26 | ||
US09/746,060 | 2000-12-22 | ||
US09/746,060 US6414156B2 (en) | 1998-10-21 | 2000-12-22 | Process for preparing azacycloalkanoylaminothiazoles |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002010163A1 true WO2002010163A1 (en) | 2002-02-07 |
Family
ID=27087817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/014155 WO2002010163A1 (en) | 1999-12-15 | 2001-05-02 | Process for preparing azacycloalkanoylaminothiazoles |
Country Status (22)
Country | Link |
---|---|
US (3) | US6414156B2 (en) |
EP (1) | EP1303514B9 (en) |
JP (1) | JP2004505080A (en) |
KR (1) | KR100764949B1 (en) |
CN (1) | CN1227250C (en) |
AT (1) | ATE299878T1 (en) |
AU (1) | AU5936901A (en) |
BR (1) | BR0112748A (en) |
CA (1) | CA2417260A1 (en) |
CY (1) | CY1105666T1 (en) |
CZ (1) | CZ2003239A3 (en) |
DE (1) | DE60112091T2 (en) |
DK (1) | DK1303514T3 (en) |
ES (1) | ES2245984T3 (en) |
HK (1) | HK1052928A1 (en) |
HU (1) | HUP0301649A3 (en) |
IL (2) | IL153748A0 (en) |
LT (1) | LT5106B (en) |
MX (1) | MXPA03000685A (en) |
PL (1) | PL365464A1 (en) |
PT (1) | PT1303514E (en) |
WO (1) | WO2002010163A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6897321B2 (en) | 1999-12-15 | 2005-05-24 | Briston Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles (LD 137e) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6262096B1 (en) | 1997-11-12 | 2001-07-17 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
US6392053B2 (en) | 1999-12-15 | 2002-05-21 | Bristol-Myers Squibb Company | Process for preparing arylacetylaminothiazoles |
US6534531B2 (en) * | 2000-04-27 | 2003-03-18 | Bristol-Myers Squibb Company | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy |
CN100457753C (en) * | 2000-07-26 | 2009-02-04 | 布里斯托尔-迈尔斯斯奎布公司 | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
DE10300124A1 (en) * | 2003-01-07 | 2004-07-15 | Bayer Ag | Process for the preparation of arylalkynes |
US7601725B2 (en) * | 2004-07-16 | 2009-10-13 | Sunesis Pharmaceuticals, Inc. | Thienopyrimidines useful as Aurora kinase inhibitors |
EP2044066A2 (en) * | 2006-06-06 | 2009-04-08 | Bristol-Myers Squibb Company | Crystalline forms of n-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl] thio]-2-thiazolyl]-4-piperidinecarboxamide |
TW200922564A (en) * | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
WO2010075542A1 (en) | 2008-12-23 | 2010-07-01 | Curis, Inc. | Cdk inhibitors |
EP3384897A1 (en) * | 2017-04-03 | 2018-10-10 | Covestro Deutschland AG | Cosmetic compositions for hair with special carbodiimides |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024416A1 (en) * | 1997-11-12 | 1999-05-20 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
US6214852B1 (en) * | 1998-10-21 | 2001-04-10 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
WO2001044242A1 (en) * | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Co. | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases |
WO2001044217A1 (en) * | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Co. | Aminothiazole inhibitors of cyclin dependent kinases |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1088049A (en) | 1975-06-03 | 1980-10-21 | Takashi Masugi | 3-substituted-7-substituted alkanamido-3-cephem-4- carboxylic acid compounds and processes for preparation thereof |
CA1201431A (en) | 1981-12-17 | 1986-03-04 | Daiei Tunemoto | .beta.-LACTAM COMPOUNDS, PROCESS FOR THE PREPARATION THEREOF AND INTERMEDIATE PRODUCTS FOR THE PREPARATION THEREOF |
NO831160L (en) | 1982-04-08 | 1983-10-10 | Erba Farmitalia | PREPARATION OF SUBSTITUTED PENEM DERIVATIVES |
JPS6339868A (en) | 1986-08-04 | 1988-02-20 | Otsuka Pharmaceut Factory Inc | Di (lower alkyl) phenol derivative |
TW205041B (en) | 1989-08-07 | 1993-05-01 | Fujisawa Pharmaceutical Co | |
DE4119756A1 (en) | 1991-06-15 | 1992-12-17 | Basf Ag | AMINOALKYL-SUBSTITUTED 5-MERCAPTOTHIAZOLE, THEIR PRODUCTION AND USE |
US5491157A (en) | 1993-05-10 | 1996-02-13 | Eastman Kodak Company | Method and composition for the prevention, control and amelioration of soilborne fungi and disease caused thereby |
IL112721A0 (en) | 1994-03-10 | 1995-05-26 | Zeneca Ltd | Azole derivatives |
JPH0859669A (en) | 1994-06-13 | 1996-03-05 | Takeda Chem Ind Ltd | Cephem compound, its production and antimicrobial agent |
JPH10510258A (en) | 1994-12-09 | 1998-10-06 | 藤沢薬品工業株式会社 | Cephem compounds and their pharmaceutical uses |
IL117620A0 (en) | 1995-03-27 | 1996-07-23 | Fujisawa Pharmaceutical Co | Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same |
AUPN801196A0 (en) | 1996-02-12 | 1996-03-07 | Fujisawa Pharmaceutical Co., Ltd. | New cephem compounds and pharmaceutical use thereof |
YU22400A (en) | 1997-10-27 | 2003-08-29 | Agouron Pharmaceuticals Inc. | Substituted 4-amino-thiazol-2-y compounds as cdks inhibitors |
US6414156B2 (en) | 1998-10-21 | 2002-07-02 | Bristol-Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles |
GB9823871D0 (en) | 1998-10-30 | 1998-12-23 | Pharmacia & Upjohn Spa | 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents |
US6534531B2 (en) | 2000-04-27 | 2003-03-18 | Bristol-Myers Squibb Company | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy |
CN100457753C (en) | 2000-07-26 | 2009-02-04 | 布里斯托尔-迈尔斯斯奎布公司 | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl] carboxamide inhibitors of cyclin dependent kinases |
-
2000
- 2000-12-22 US US09/746,060 patent/US6414156B2/en not_active Expired - Lifetime
-
2001
- 2001-05-02 CA CA002417260A patent/CA2417260A1/en not_active Abandoned
- 2001-05-02 AT AT01932879T patent/ATE299878T1/en not_active IP Right Cessation
- 2001-05-02 DK DK01932879T patent/DK1303514T3/en active
- 2001-05-02 DE DE60112091T patent/DE60112091T2/en not_active Expired - Fee Related
- 2001-05-02 PL PL01365464A patent/PL365464A1/en not_active Application Discontinuation
- 2001-05-02 AU AU5936901A patent/AU5936901A/en active Pending
- 2001-05-02 JP JP2002515892A patent/JP2004505080A/en not_active Withdrawn
- 2001-05-02 PT PT01932879T patent/PT1303514E/en unknown
- 2001-05-02 WO PCT/US2001/014155 patent/WO2002010163A1/en active IP Right Grant
- 2001-05-02 HU HU0301649A patent/HUP0301649A3/en unknown
- 2001-05-02 KR KR1020037001143A patent/KR100764949B1/en not_active IP Right Cessation
- 2001-05-02 EP EP01932879A patent/EP1303514B9/en not_active Expired - Lifetime
- 2001-05-02 IL IL15374801A patent/IL153748A0/en unknown
- 2001-05-02 ES ES01932879T patent/ES2245984T3/en not_active Expired - Lifetime
- 2001-05-02 CZ CZ2003239A patent/CZ2003239A3/en unknown
- 2001-05-02 BR BR0112748-9A patent/BR0112748A/en not_active Application Discontinuation
- 2001-05-02 CN CNB018131786A patent/CN1227250C/en not_active Expired - Fee Related
- 2001-05-02 MX MXPA03000685A patent/MXPA03000685A/en active IP Right Grant
-
2002
- 2002-03-18 US US10/100,129 patent/US6639074B2/en not_active Expired - Lifetime
- 2002-12-30 IL IL153748A patent/IL153748A/en not_active IP Right Cessation
-
2003
- 2003-01-07 LT LT2003001A patent/LT5106B/en not_active IP Right Cessation
- 2003-05-13 HK HK03103394A patent/HK1052928A1/en not_active IP Right Cessation
- 2003-08-12 US US10/639,272 patent/US6897321B2/en not_active Expired - Lifetime
-
2005
- 2005-09-02 CY CY20051101065T patent/CY1105666T1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999024416A1 (en) * | 1997-11-12 | 1999-05-20 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
US6214852B1 (en) * | 1998-10-21 | 2001-04-10 | Bristol-Myers Squibb Company | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
WO2001044242A1 (en) * | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Co. | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]carboxamide inhibitors of cyclin dependent kinases |
WO2001044241A1 (en) * | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Co. | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases |
WO2001044217A1 (en) * | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Co. | Aminothiazole inhibitors of cyclin dependent kinases |
Non-Patent Citations (3)
Title |
---|
GANELLIN C R ET AL: "Design of a potent non-thiourea H3-receptor histamine antagonist", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 17, 1995, pages 3342 - 3350, XP002074789 * |
HALL J H ET AL: "Syntheses and photophysical properties of some 5(2)-aryl-2(5)-(4-pyridyl)oxazoles and related oxadiazoles and furans", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 29, no. 5, 1992, pages 1245 - 1273, XP002181697 * |
SCOTT C R ET AL: "The antibacterial activity of a series of quaternaries prepared from hexamethylentetramine and halohydrocarbons", APPLIED MICROBIOLOGY, vol. 10, 1962, pages 211 - 216, XP000655121 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6897321B2 (en) | 1999-12-15 | 2005-05-24 | Briston Myers Squibb Company | Process for preparing azacycloalkanoylaminothiazoles (LD 137e) |
Also Published As
Publication number | Publication date |
---|---|
PT1303514E (en) | 2005-11-30 |
HUP0301649A2 (en) | 2003-12-29 |
KR20030064736A (en) | 2003-08-02 |
DE60112091T2 (en) | 2006-04-20 |
EP1303514B1 (en) | 2005-07-20 |
EP1303514B9 (en) | 2006-11-08 |
ATE299878T1 (en) | 2005-08-15 |
US6414156B2 (en) | 2002-07-02 |
US6897321B2 (en) | 2005-05-24 |
HK1052928A1 (en) | 2003-10-03 |
US20010006976A1 (en) | 2001-07-05 |
CN1449395A (en) | 2003-10-15 |
CZ2003239A3 (en) | 2003-08-13 |
AU5936901A (en) | 2002-02-13 |
JP2004505080A (en) | 2004-02-19 |
KR100764949B1 (en) | 2007-10-08 |
DE60112091D1 (en) | 2005-08-25 |
CA2417260A1 (en) | 2002-02-07 |
PL365464A1 (en) | 2005-01-10 |
US20040063767A1 (en) | 2004-04-01 |
US20020099217A1 (en) | 2002-07-25 |
CN1227250C (en) | 2005-11-16 |
HUP0301649A3 (en) | 2008-04-28 |
IL153748A (en) | 2009-07-20 |
CY1105666T1 (en) | 2010-12-22 |
US6639074B2 (en) | 2003-10-28 |
LT5106B (en) | 2004-02-25 |
DK1303514T3 (en) | 2005-10-10 |
ES2245984T3 (en) | 2006-02-01 |
IL153748A0 (en) | 2003-07-06 |
BR0112748A (en) | 2003-09-09 |
EP1303514A1 (en) | 2003-04-23 |
MXPA03000685A (en) | 2003-09-10 |
LT2003001A (en) | 2003-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1303514B1 (en) | Process for preparing azacycloalkanoylaminothiazoles | |
WO2001044191A1 (en) | 4-aminopiperidine derivatives and their use as medicine | |
WO2005014553A1 (en) | Novel gamma-secretase inhibitors | |
JP6469214B2 (en) | Novel chiral synthesis of N-acyl- (3-substituted)-(8-substituted) -5,6-dihydro- [1,2,4] triazolo [4,3-a] pyrazine | |
JP2010500405A (en) | Methods and intermediates for the synthesis of 2- (quinolin-5-yl) -4,5 disubstituted-azole derivatives | |
US6392053B2 (en) | Process for preparing arylacetylaminothiazoles | |
AU2001257493A1 (en) | Process for preparing arylacetylaminothiazoles | |
AU2001259369B2 (en) | Process for preparing azacycloalkanoylaminothiazoles | |
AU2001259369A1 (en) | Process for preparing azacycloalkanoylaminothiazoles | |
AU715100B2 (en) | Thienopyridine derivatives and their use | |
US20040171842A1 (en) | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis | |
JP2011504164A (en) | Condensed thiazole derivatives as kinase inhibitors | |
Golovchenko et al. | Synthesis of novel phosphorylated peptidomimetics which contain ω-haloalkyl and ω-thiocyanoethyl residues | |
AU2003258536A1 (en) | Process for the preparation of amino-pyrrolidine derivatives | |
JPS62500873A (en) | New method for producing cephalosporin derivatives | |
KR100361829B1 (en) | The process for preparing a ceftriaxone from reactive organic acid derivatives | |
WO2007034183A2 (en) | Process for the preparation of 4-aminopyrazole derivatives | |
US20050124673A1 (en) | Methods of preparing compounds useful as protease inhibitors | |
KR100361828B1 (en) | Method for preparing cytotactile from reactive organic acid derivative | |
KR0182414B1 (en) | The process for preparation of cephalosporin compounds | |
MXPA06006263A (en) | Methods of preparing compounds useful as protease inhibitors | |
PL212788B1 (en) | The manner of production of alkylo 3-(acyloamino)- 1H- pirasalo- carboxylan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 153748 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 36/MUMNP/2003 Country of ref document: IN |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 018131786 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/000685 Country of ref document: MX Ref document number: 2001932879 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2003-239 Country of ref document: CZ Ref document number: 2417260 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037001143 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001259369 Country of ref document: AU |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 2001932879 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020037001143 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2003-239 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001932879 Country of ref document: EP |